Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Price History  |  Ratios  |  Insiders

Stock Quote Today & Recent News Nurix Therapeutics Inc NRIX

Healthcare Biotechnology
Nurix Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and antibody therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-5948, an orally bioavailable BTK degrader, that is in Phase 1B/2 clinical trials for the treatment of relapsed or refractory B... see more

Current News (NDAQ:NRIX)

Nurix Therapeutics Outlines 2026 Goals and Objectives for Advancing Bexobrutideg and Its Pipeline of Novel Degrader-Based Medicines in Cancer and Autoimmune Diseases

GlobeNewswire 12 days ago

Nurix Therapeutics to Participate in the 44th Annual J.P. Morgan Healthcare Conference

GlobeNewswire January 5, 2026

Nurix Therapeutics Presents New Data from the Phase 1 Trial of Bexobrutideg (NX-5948) in Waldenström Macroglobulinemia at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition

GlobeNewswire December 8, 2025

Nurix Therapeutics Presents New Data Demonstrating Durable, Deepening Responses in Phase 1 Trial of Bexobrutideg (NX-5948) in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) at the 67th American Society of Hematology (ASH) Annual Meeting & Exposition

GlobeNewswire December 6, 2025

Nurix Therapeutics Announces Webcast to Review New and Updated Data from the Phase 1 Clinical Trial of BTK Degrader Bexobrutideg (NX-5948) To Be Presented at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition

GlobeNewswire December 1, 2025

Nurix Therapeutics to Participate in the Piper Sandler 37th Annual Healthcare Conference

GlobeNewswire November 25, 2025

Nurix Therapeutics Appoints Accomplished Biopharmaceutical Leader Roger Dansey, M.D., to Its Board of Directors

GlobeNewswire November 10, 2025

Nurix Therapeutics Presents New Translational Data from First-in-Human Clinical Trial of Oral CBL-B Inhibitor NX-1607 Demonstrating Immune Activation and Tumor Microenvironment Remodeling

GlobeNewswire November 7, 2025

Nurix Therapeutics Announces Presentations at the 67th American Society of Hematology (ASH) Annual Meeting

GlobeNewswire November 3, 2025
View More News ››

Opinion & Analysis (NDAQ:NRIX)

No current opinion is available.
View More Opinion ››

Bullboard Posts (NDAQ:NRIX)

Nurix Therapeutics, Inc. (NRIX): A Promising Biotech Poised

http://beyondspx.com/2024/07/31/nurix-therapeutics-inc-nrix-a-promising-biotech-poised-for-significant-growth/
MikeTester - August 2, 2024
View more Bullboard ››

dynaCERT Inc.

dynaCERT Inc.

dynaCERT Inc., together with its subsidiaries, engages in the design, engineering, manufacture, testing, and distribution of ...
View More »

Podcasts